During the past decade, Daniel Furst, MD conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Daniel Furst, MD" are "Digital Ulcers" (2 trials) and "Systemic Sclerosis" (1 trials). Many other conditions were trialed in "Daniel Furst, MD" in a lesser frequency.

Most popular intervention types in "Daniel Furst, MD" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Bosentan 125 mg" (2 trials), "Bosentan 62.5 mg" (2 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Daniel Furst, MD" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Daniel Furst, MD". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Daniel Furst, MD, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Daniel Furst, MD, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".